Advanced Filters
noise

Waukesha, Wisconsin Clinical Trials

A listing of Waukesha, Wisconsin clinical trials actively recruiting patient volunteers.

Found 412 clinical trials
R Ratko Yurac, MD

The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study

To determine the accuracy of serum NF-L and GFAP levels (ie the biomarkers) at different time points postinjury for predicting the severity of neurologic impairment at 6 months postinjury as either motor complete (AIS grade A/B) or motor incomplete (AIS grade C/D) a group of patients who suffer traumatic spinal …

19 years of age All Phase N/A
J Julie Biller, MD

Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis

Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in …

18 years of age All Phase N/A
N Nicole L Lohr, MD PhD

Peripheral Blood Flow Responses to Electromagnetic Energy

This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.

18 - 59 years of age All Phase N/A
M Medical College of Wisconsin Cancer Center Clinical Trials Office

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis

This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.

18 years of age All Phase N/A
C Cancer Clinical Trials Team

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved …

18 years of age All Phase 2
A Achuthan Sourianarayanane, MD

Diagnosis of Fatty Liver With Outpatient Ultrasound

This study will evaluate whether ultrasound performed during outpatient visit is effective in early diagnosis of fatty liver.

18 - 80 years of age All Phase N/A
C Cancer Clinical Trials Team

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will …

18 years of age All Phase 2
S Site Public Contact

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without a KMT2A gene rearrangement (KMT2A-germline \[G\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) …

- 365 years of age All Phase 2
S Sidney E Schoenrock, MA

Language Processing and TMS

This study will examine the effect of TMS on people with stroke and aphasia as well as healthy individuals.

18 - 85 years of age All Phase N/A
G Guru Murthy, M.D.

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).

18 years of age All Phase 1

Simplify language using AI